Lymphoma of the Eyelid: An International Multicenter Retrospective Study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Lymphoma of the Eyelid : An International Multicenter Retrospective Study. / Svendsen, Frederik Holm; Rasmussen, Peter Kristian; Coupland, Sarah E.; Esmaeli, Bita; Finger, Paul T.; Graue, Gerardo F.; Grossniklaus, Hans E.; Honavar, Santosh G.; Khong, Jwu Jin; McKelvie, Penelope A.; Mulay, Kaustubh; Ralfkiaer, Elisabeth; Sjo, Lene Dissing; Vemuganti, Geeta K.; Thuro, Bradley A.; Curtin, Jeremy; Heegaard, Steffen.

I: American Journal of Ophthalmology, Bind 177, 05.2017, s. 58-68.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Svendsen, FH, Rasmussen, PK, Coupland, SE, Esmaeli, B, Finger, PT, Graue, GF, Grossniklaus, HE, Honavar, SG, Khong, JJ, McKelvie, PA, Mulay, K, Ralfkiaer, E, Sjo, LD, Vemuganti, GK, Thuro, BA, Curtin, J & Heegaard, S 2017, 'Lymphoma of the Eyelid: An International Multicenter Retrospective Study', American Journal of Ophthalmology, bind 177, s. 58-68. https://doi.org/10.1016/j.ajo.2017.02.004

APA

Svendsen, F. H., Rasmussen, P. K., Coupland, S. E., Esmaeli, B., Finger, P. T., Graue, G. F., Grossniklaus, H. E., Honavar, S. G., Khong, J. J., McKelvie, P. A., Mulay, K., Ralfkiaer, E., Sjo, L. D., Vemuganti, G. K., Thuro, B. A., Curtin, J., & Heegaard, S. (2017). Lymphoma of the Eyelid: An International Multicenter Retrospective Study. American Journal of Ophthalmology, 177, 58-68. https://doi.org/10.1016/j.ajo.2017.02.004

Vancouver

Svendsen FH, Rasmussen PK, Coupland SE, Esmaeli B, Finger PT, Graue GF o.a. Lymphoma of the Eyelid: An International Multicenter Retrospective Study. American Journal of Ophthalmology. 2017 maj;177:58-68. https://doi.org/10.1016/j.ajo.2017.02.004

Author

Svendsen, Frederik Holm ; Rasmussen, Peter Kristian ; Coupland, Sarah E. ; Esmaeli, Bita ; Finger, Paul T. ; Graue, Gerardo F. ; Grossniklaus, Hans E. ; Honavar, Santosh G. ; Khong, Jwu Jin ; McKelvie, Penelope A. ; Mulay, Kaustubh ; Ralfkiaer, Elisabeth ; Sjo, Lene Dissing ; Vemuganti, Geeta K. ; Thuro, Bradley A. ; Curtin, Jeremy ; Heegaard, Steffen. / Lymphoma of the Eyelid : An International Multicenter Retrospective Study. I: American Journal of Ophthalmology. 2017 ; Bind 177. s. 58-68.

Bibtex

@article{e3df8d205f7e4a2e817a2204ea8f381b,
title = "Lymphoma of the Eyelid: An International Multicenter Retrospective Study",
abstract = "PurposeTo document subtype-specific clinical features of lymphoma of the eyelid, and their effect on patient outcome.DesignRetrospective observational case series.MethodsPatient data were collected from 7 international eye cancer centers from January 1, 1980 through December 31, 2015. The cases included primary and secondary lymphomas affecting the eyelid. Overall survival, disease-specific survival (DSS), and progression-free survival were the primary endpoints.ResultsEighty-six patients were included. Mean age was 63 years and 47 (55%) were male. Non-Hodgkin B-cell lymphomas constituted 83% (n = 71) and T-cell lymphomas constituted 17% (n = 15). The most common subtypes were extranodal marginal-zone lymphoma (EMZL) (37% [n = 32]), follicular lymphoma (FL) (23% [n = 20]), diffuse large B-cell lymphoma (DLBCL) (10% [n = 9]), mantle cell lymphoma (MCL) (8% [n = 7]), and mycosis fungoides (MF) (9% [n = 8]). EMZL had a female predilection (69% [22 of 32]), whereas MCL (71% [5 of 7]) and MF (88% [7 of 8]) had a male predominance. MCL (57% [4 of 7]), DLBCL (56% [5 of 9]), and MF (88% [7 of 8]) were frequently secondary lymphomas. Localized EMZL and FL were mostly treated with external beam radiation therapy, whereas DLBCL, MCL, and high Ann Arbor stage EMZL and FL were frequently treated with chemotherapy. DLBCL and MCL had a poor prognosis (5-year DSS, 21% and 50%, respectively), whereas EMZL, FL, and MF had a good prognosis (5-year DSS, 88%, 88% and 86%, respectively).ConclusionsLymphoma of the eyelid consists mainly of the lymphoma subtypes EMZL, FL, DLBCL, MCL, and MF. High-grade DLBCL and MCL, as well as MF, are frequently secondary eyelid lymphomas. The main predictor of outcome was the histologic subtype: EMZL, FL, and MF had a significantly better prognosis than MCL and DLBCL.",
author = "Svendsen, {Frederik Holm} and Rasmussen, {Peter Kristian} and Coupland, {Sarah E.} and Bita Esmaeli and Finger, {Paul T.} and Graue, {Gerardo F.} and Grossniklaus, {Hans E.} and Honavar, {Santosh G.} and Khong, {Jwu Jin} and McKelvie, {Penelope A.} and Kaustubh Mulay and Elisabeth Ralfkiaer and Sjo, {Lene Dissing} and Vemuganti, {Geeta K.} and Thuro, {Bradley A.} and Jeremy Curtin and Steffen Heegaard",
year = "2017",
month = may,
doi = "10.1016/j.ajo.2017.02.004",
language = "English",
volume = "177",
pages = "58--68",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Lymphoma of the Eyelid

T2 - An International Multicenter Retrospective Study

AU - Svendsen, Frederik Holm

AU - Rasmussen, Peter Kristian

AU - Coupland, Sarah E.

AU - Esmaeli, Bita

AU - Finger, Paul T.

AU - Graue, Gerardo F.

AU - Grossniklaus, Hans E.

AU - Honavar, Santosh G.

AU - Khong, Jwu Jin

AU - McKelvie, Penelope A.

AU - Mulay, Kaustubh

AU - Ralfkiaer, Elisabeth

AU - Sjo, Lene Dissing

AU - Vemuganti, Geeta K.

AU - Thuro, Bradley A.

AU - Curtin, Jeremy

AU - Heegaard, Steffen

PY - 2017/5

Y1 - 2017/5

N2 - PurposeTo document subtype-specific clinical features of lymphoma of the eyelid, and their effect on patient outcome.DesignRetrospective observational case series.MethodsPatient data were collected from 7 international eye cancer centers from January 1, 1980 through December 31, 2015. The cases included primary and secondary lymphomas affecting the eyelid. Overall survival, disease-specific survival (DSS), and progression-free survival were the primary endpoints.ResultsEighty-six patients were included. Mean age was 63 years and 47 (55%) were male. Non-Hodgkin B-cell lymphomas constituted 83% (n = 71) and T-cell lymphomas constituted 17% (n = 15). The most common subtypes were extranodal marginal-zone lymphoma (EMZL) (37% [n = 32]), follicular lymphoma (FL) (23% [n = 20]), diffuse large B-cell lymphoma (DLBCL) (10% [n = 9]), mantle cell lymphoma (MCL) (8% [n = 7]), and mycosis fungoides (MF) (9% [n = 8]). EMZL had a female predilection (69% [22 of 32]), whereas MCL (71% [5 of 7]) and MF (88% [7 of 8]) had a male predominance. MCL (57% [4 of 7]), DLBCL (56% [5 of 9]), and MF (88% [7 of 8]) were frequently secondary lymphomas. Localized EMZL and FL were mostly treated with external beam radiation therapy, whereas DLBCL, MCL, and high Ann Arbor stage EMZL and FL were frequently treated with chemotherapy. DLBCL and MCL had a poor prognosis (5-year DSS, 21% and 50%, respectively), whereas EMZL, FL, and MF had a good prognosis (5-year DSS, 88%, 88% and 86%, respectively).ConclusionsLymphoma of the eyelid consists mainly of the lymphoma subtypes EMZL, FL, DLBCL, MCL, and MF. High-grade DLBCL and MCL, as well as MF, are frequently secondary eyelid lymphomas. The main predictor of outcome was the histologic subtype: EMZL, FL, and MF had a significantly better prognosis than MCL and DLBCL.

AB - PurposeTo document subtype-specific clinical features of lymphoma of the eyelid, and their effect on patient outcome.DesignRetrospective observational case series.MethodsPatient data were collected from 7 international eye cancer centers from January 1, 1980 through December 31, 2015. The cases included primary and secondary lymphomas affecting the eyelid. Overall survival, disease-specific survival (DSS), and progression-free survival were the primary endpoints.ResultsEighty-six patients were included. Mean age was 63 years and 47 (55%) were male. Non-Hodgkin B-cell lymphomas constituted 83% (n = 71) and T-cell lymphomas constituted 17% (n = 15). The most common subtypes were extranodal marginal-zone lymphoma (EMZL) (37% [n = 32]), follicular lymphoma (FL) (23% [n = 20]), diffuse large B-cell lymphoma (DLBCL) (10% [n = 9]), mantle cell lymphoma (MCL) (8% [n = 7]), and mycosis fungoides (MF) (9% [n = 8]). EMZL had a female predilection (69% [22 of 32]), whereas MCL (71% [5 of 7]) and MF (88% [7 of 8]) had a male predominance. MCL (57% [4 of 7]), DLBCL (56% [5 of 9]), and MF (88% [7 of 8]) were frequently secondary lymphomas. Localized EMZL and FL were mostly treated with external beam radiation therapy, whereas DLBCL, MCL, and high Ann Arbor stage EMZL and FL were frequently treated with chemotherapy. DLBCL and MCL had a poor prognosis (5-year DSS, 21% and 50%, respectively), whereas EMZL, FL, and MF had a good prognosis (5-year DSS, 88%, 88% and 86%, respectively).ConclusionsLymphoma of the eyelid consists mainly of the lymphoma subtypes EMZL, FL, DLBCL, MCL, and MF. High-grade DLBCL and MCL, as well as MF, are frequently secondary eyelid lymphomas. The main predictor of outcome was the histologic subtype: EMZL, FL, and MF had a significantly better prognosis than MCL and DLBCL.

U2 - 10.1016/j.ajo.2017.02.004

DO - 10.1016/j.ajo.2017.02.004

M3 - Journal article

C2 - 28209503

VL - 177

SP - 58

EP - 68

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

ER -

ID: 182543067